

1 **Evaluation of Alinity m CMV assay performance for detecting CMV in plasma,**
2 **cerebrospinal fluid, and bronchoalveolar lavage specimens**

3

4 **Running title:** Alinity m CMV Assay Performance

5

6 Joshua Kostera¹, Mark Hubbard², Dillon Jackson², Rachael M. Liesman³

7

8 ¹ Abbott Molecular, Des Plaines, IL, USA

9 ² Department of Pathology and Laboratory Medicine, The University of Kansas Health

10 System, Kansas City, KS, USA

11 ³ Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

12

13 **Corresponding author:** Rachael Liesman

14 8701 W Watertown Plank Road, Milwaukee WI 53226

15 414-805-6972

16 rliesman@mcw.edu

17

18 **Word Count**

19 Abstract: 204

20 Manuscript: 1829

21 **Funding**

22 This study was funded by Molecular Diagnostics of Abbott.

23

24 **Conflict of Interest Declaration**

25 Joshua Kostera is an employee of Abbott Laboratories

26 Rachael Liesman has received research support from Abbott Laboratories (reagents,

27 supplies)

28

29 **Abstract**

30 **Introduction:** Rapid and accurate detection of cytomegalovirus (CMV) infection and
31 reactivation is crucial to preventing adverse outcomes in immunocompromised individuals,
32 especially in transplant recipients. Current PCR-based assays were developed for use with
33 plasma specimens, but CMV is present in bronchoalveolar lavage fluid (BAL) in
34 immunocompromised patients with CMV pneumonia and has also been detected in
35 cerebrospinal fluid (CSF).

36 **Objectives:** We evaluated the performance of the Abbott Alinity m CMV assay compared to
37 the Abbott RealTime CMV assay for quantification of CMV in plasma, BAL, and CSF
38 specimens.

39 **Methods:** Analytical performance, including linearity, precision, and limit of detection, was
40 established for plasma, BAL, and CSF specimen types using reference CMV control material
41 (SeraCare). To evaluate clinical performance, 190 plasma specimens, 78 BAL specimens,
42 and 26 CSF specimens were tested with the Alinity m assay and compared to the RealTime
43 CMV assay.

44 **Results:** The Alinity m CMV assay showed high precision (SD <0.01 to 0.13) within the
45 quantifiable range (1.49-8.00 log₁₀ IU/mL) for all 3 specimen types, with strong clinical
46 correlation to the RealTime CMV assay results ($r^2=0.9779$ for plasma, $r^2=0.9373$ for BAL,
47 $r^2=0.9889$ for CSF).

48 **Conclusion:** The Alinity m CMV assay may be useful for rapid detection of CMV in plasma,
49 BAL, and CSF specimens.

50 **Introduction**

51 Cytomegalovirus is highly prevalent worldwide(1). After initial infection, CMV becomes latent
52 and can be reactivated in response to stress or suppression of the immune response (2). In
53 immunocompetent individuals, primary CMV infection may be asymptomatic or mildly
54 symptomatic; however, infection or reactivation of latent CMV in immunocompromised
55 individuals is associated with severe to fatal outcomes(2-4). Individuals with hematopoietic
56 stem cell or solid organ transplants are at high risk of graft rejection or loss, multi-organ
57 failure, and death as a consequence of CMV reactivation(5). Ongoing monitoring of CMV
58 DNA load in transplant recipients is therefore essential to prevent CMV-related adverse
59 outcomes(6).

60

61 Highly sensitive and specific nucleic acid amplification tests (NAATs) for quantifying CMV
62 DNA in plasma have been developed for the detection of CMV reactivation and response to
63 anti-CMV treatment(7).CMV can also be detected in bronchoalveolar lavage (BAL)
64 specimens from transplant recipients and immunocompromised patients with suspected
65 CMV pneumonia(8-11). CMV infection of the central nervous system may occur in severely
66 immunosuppressed patients, such as those with advanced HIV infection, and CMV may be
67 detectable in the cerebrospinal fluid (CSF)(6, 12). Here, we evaluated the performance of
68 the Alinity m CMV assay compared to the Abbott RealTime CMV assay for quantification of
69 CMV viral load in plasma specimens and detection of CMV in CSF and BAL specimens.

70

71 **Materials and Methods**

72 **Specimens**

73 Deidentified remnant specimens (plasma, CSF, and BAL) from patients were utilized to
74 assess the performance of the Alinity m CMV assay. All assays were run in the central
75 laboratory of a large urban tertiary care hospital. The study was determined to be exempt by
76 The University of Kansas Health System Institutional Review Board.

77

78 **Assay platforms**

79 The Alinity m CMV assay is a real-time PCR-based test that targets regions within the UL34
80 and UL80.5 genes to detect and quantify CMV DNA in human plasma, with a reported
81 quantitative range of 1.48 to 8.00 log₁₀ IU/mL. The RealTime CMV assay is performed on
82 the *m2000* platform, consisting of the *m2000sp* for sample preparation and *m2000rt* for
83 amplification and detection. The RealTime CMV assay has the same target region as
84 the Alinity m CMV assay with a quantitative range of 1.70 to 8.19 log₁₀ IU/mL.

85

86 **Analytical evaluation**

87 To assess limit of detection (LoD) in plasma specimens, the ExactDX (EDX) CMV LoD panel
88 (Exact Diagnostics, Fort Worth, TX) was tested at 1.65 log₁₀ IU/mL and diluted in negative
89 plasma to 1.48 log₁₀ IU/mL; each level was tested in replicates of 20 across 5 days. The
90 LoD was assessed in BAL and CSF by diluting the EDX panel to 2.00, 1.70, and 1.48 log₁₀
91 IU/mL in negative matrix and each level was tested in replicates of 15. The lowest
92 concentration with 100% qualitative detection was determined as the LoD. Precision for
93 plasma specimens was assessed with EDX material at high (5.70 log₁₀ IU/mL) and low (3.0
94 log₁₀ IU/mL) concentrations tested in triplicate daily for 6 days. Linearity for plasma
95 specimens was assessed with the EDX CMV panel, consisting of 6 levels (2.30, 2.60, 3.60,
96 4.60, 5.60, and 6.60 log₁₀ IU/mL) tested in duplicate daily over 4 days. To assess linearity
97 and precision of the Alinity m CMV assay in BAL and CSF specimens, CMV-negative pooled
98 BAL or CSF specimens were spiked with a CMV-positive plasma sample at final
99 concentrations of 2.60, 4.60, and 6.60 log₁₀ IU/mL and tested in triplicate daily for 5 days.
100 External Alinity CMV quality control material at high and low concentrations were also tested
101 daily.

102

103 **Clinical specimen evaluation**

104 To assess accuracy, a total of 190 deidentified remnant plasma specimens initially tested on
105 the RealTime CMV assay as part of routine clinical care were tested on the Alinity m CMV

106 assay. Specimens were stored refrigerated (2-8°C) for ≤48 hours (n=81) or frozen (-20°C;
107 n=109) prior to testing. Additionally, 78 BAL specimens and 26 CSF specimens initially
108 tested using the RealTime CMV assay were tested on the Alinity m CMV assay. Specimens
109 were stored refrigerated (2-8°C) for ≤48 hours (BAL n=14; CSF n=7) or frozen (-20°C; BAL
110 n=64; CSF n=19) prior to testing. Because all clinical CSF specimens were negative for
111 CMV, positive CSF specimens were generated by spiking negative pooled CSF with a
112 known CMV-positive plasma specimen (7.1 log₁₀ IU/mL), which was then serially diluted to
113 the analytical measurement range of 1.6 to 6.6 log₁₀ IU/mL. The dilutions were tested on
114 both the RealTime CMV assay and Alinity m CMV assay.

115

116 **Statistical analysis**

117 All analyses were performed using PC SAS (version 9.4) software (SAS, Cary, NC, USA).
118 The percent positive agreement (PPA), negative percent agreement (NPA), and overall
119 percent agreement (OPA) were calculated to determine qualitative method agreement.
120 Variability is expressed as standard deviation (SD) and percent coefficient of variation
121 (%CV). Correlation analysis was performed only on specimens with quantifiable results and
122 was evaluated using by Deming regression analysis and Bland-Altman plots.

123

124 **Results**

125 **Analytical performance**

126 The Alinity m CMV assay was determined to be highly reproducible across all 3 specimen
127 types (Table 1). In plasma, the standard deviation (SD) range was 0.07-0.11, inter-assay
128 coefficients of variation (%CV) ranged from 1.27% to 3.45%, and intra-assay %CV from
129 0.84% to 2.32%. In BAL, SD ranged from 0.06-0.13 and inter- and intra-assay %CV ranged
130 from 1.38% to 4.74% and 1.17% to 3.76%, respectively. In CSF, SD was below 0.1 and both
131 inter- and intra-assay %CVs ranged from 0.71% to 2.12%. The Alinity m CMV assay
132 demonstrated excellent linearity in plasma across the quantifiable range (1.49 and 8.00
133 log₁₀ IU/mL), consistent with the assay package insert (Figure 1A). Linearity was also

134 demonstrated in BAL and CSF specimens across the analytical measurement range (Figure
135 1B and 1C, respectively). The LoD for plasma, BAL, and CSF specimen types was
136 determined to be 1.48 log₁₀ IU/mL (30 IU/mL) for all matrices. Trend analysis of the high
137 EQC material from 2 reagent lots by Levey-Jennings plot demonstrated 2 points outside of
138 ±2SD acceptable range and no points outside of ±3SD acceptable range across 29 non-
139 consecutive days of testing (Figure 2A). A similar analysis of the low EQC material showed 1
140 point outside of ±2SD and no points outside of ±3SD acceptable ranges (Figure 2B).

141

142 **Clinical performance**

143 One hundred and ninety plasma specimens were included in this study and qualitative
144 positive, negative, and overall agreement rates were 95%, 89%, and 93%, respectively
145 (Table 2). Fourteen specimens were discordant, with 8 specimens detected only by the
146 Alinity m assay and 6 specimens detected only by the RealTime assay. All 14 discordant
147 plasma specimens were detected below the limit of quantification of the respective assay
148 (<50 IU/mL for the RealTime assay; <30 IU/mL for the Alinity m assay), consistent with
149 detection variability at the LoD. A total of 97 specimens were within the quantifiable range of
150 both assays and were used to assess clinical correlation between the assays. Deming
151 regression analysis demonstrated high correlation between the 2 assays ($R^2 = 0.9779$; slope
152 = 1.0032) (Figure 3A). A Bland-Altman plot was used to further analyze correlation between
153 the methods (Figure 3B). Overall bias was -0.06 log₁₀ IU/mL, with only 1 specimen
154 demonstrating a bias >0.5 log₁₀ IU/mL.

155

156 Seventy-eight BAL specimens were assessed for qualitative accuracy, with positive,
157 negative, and overall agreement rates of 100%, 87%, and 95%, respectively (Table 2). Four
158 total specimens were discordant, which were detected by the Alinity m assay below the
159 quantifiable range (<30 IU/mL). A total of 40 specimens were within the quantifiable range of
160 both assays. Deming regression analysis showed high correlation between the assays
161 ($R^2=0.9373$; slope 0.9781) (Figure 3C). Bland-Altman analysis demonstrated an overall bias

162 of -0.28 log₁₀ IU/mL (Figure 3D). Ten specimens (25%) had quantitative values with a bias
163 >0.5 log₁₀ IU/mL, with 9 specimens resulting in a >0.5 log₁₀ IU/mL higher CMV DNA load
164 from the *RealTime* assay and 1 specimen resulting in a >0.5 log₁₀ IU/mL higher CMV DNA
165 load when tested with the Alinity m assay.

166

167 All negative and contrived positive CSF specimens were concordant between the *RealTime*
168 and Alinity m CMV assays (Table 2). For the 6 contrived positive specimens, Deming
169 regression analysis showed high correlation ($R^2=0.9889$; slope 0.9489) between the 2
170 assays (Figure 3E). Overall bias was -0.20 log₁₀ IU/mL and 1 specimen demonstrated bias
171 >0.5 log₁₀ IU/mL (Figure 3F).

172

173 **Discussion**

174 In this study, we assessed the analytical performance of the Alinity m CMV assay for
175 quantitation of CMV viral load in plasma, CSF, and BAL specimens as compared to the
176 *RealTime* CMV assay. Overall, the Alinity m assay demonstrated excellent linearity,
177 precision, and clinical correlation across all 3 specimen types. Additionally, the LoD
178 determined in this study for plasma samples (30 IU/mL) was consistent with the
179 manufacturer's package insert, and an equivalent LoD was also established for BAL and
180 CSF specimens, which were not assessed by the manufacturer.

181

182 Our study findings are consistent with previous studies that have demonstrated the detection
183 of CMV in BAL or bronchial brush specimens with PCR-based tests to diagnose CMV
184 pneumonia in immunocompromised patients, patients with hematologic malignancies, and
185 after transplantation(8, 13, 14). Previous studies have reported difficulty in defining
186 quantitative cut-offs for CMV viral load in BAL specimens associated with CMV
187 pneumonia(10). A recent prospective study identified a CMV load of 831 IU/mL as the
188 diagnostic cut-off for CMV pneumonia; however, the authors recommended NAAT as a
189 complementary test to bronchoscopy for definitive diagnosis(11). Further studies are needed

190 to establish clinical decision points for CMV viral load values. Although we assessed the
191 quantitative performance of this assay in CSF and BAL specimens, we report CMV testing
192 from these specimens qualitatively.

193

194 In our comparative analysis, we found high percent agreement and correlation of results
195 between Alinity m CMV and the RealTime CMV assay for all 3 specimen types. Of 294 total
196 specimens assessed in this study, 18 (6%) were considered discordant. Most discordant
197 samples were detected only by the Alinity m assay (n=12), which may be due to the lower
198 LoD of the Alinity m assay as compared to the RealTime assay. Further, all discordant
199 samples were detected below the limit of quantification, consistent with variable detection of
200 viral DNA at the LoD. Further, no significant bias was demonstrated when comparing plasma
201 specimens tested on both assays, which allows for a change of method without the need for
202 re-baselining of patients. Greater bias was demonstrated when assessing clinical correlation
203 of CMV DNA load in BAL specimens suggesting a potential need for re-baselining patients
204 or reestablishing cut-off values for laboratories reporting quantitative results in BAL
205 specimens.

206

207 In our single-center study, only a limited number of clinical CSF specimens were available
208 for testing, and all were found to be negative for CMV. Larger studies are needed to
209 establish the clinical performance of the Alinity m CMV assay with CSF specimens.

210

211 In conclusion, we found that the Alinity m CMV assay demonstrated high precision and
212 accuracy for the quantitation of CMV DNA in both contrived panels and clinical specimens.
213 The Alinity m platform allows rapid reporting of test results, which may improve turnaround
214 time allowing for optimized detection and monitoring of CMV in at-risk patients.

215

216 **Acknowledgements**

217 This study was funded by Molecular Diagnostics of Abbott. Stacey Tobin, PhD, provided
218 editorial support for manuscript preparation, with compensation from Abbott Laboratories.

219

220

221 **References**

- 222 1. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleeschauwer B, Griffiths P.
223 2019. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic
224 review and meta-analysis. *Rev Med Virol* 29:e2034.
- 225 2. Griffiths P, Baraniak I, Reeves M. 2015. The pathogenesis of human
226 cytomegalovirus. *J Pathol* 235:288-97.
- 227 3. Boeckh M, Geballe AP. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. *J*
228 *Clin Invest* 121:1673-80.
- 229 4. Camargo JF, Komanduri KV. 2017. Emerging concepts in cytomegalovirus infection
230 following hematopoietic stem cell transplantation. *Hematol Oncol Stem Cell Ther*
231 10:233-238.
- 232 5. Razonable RR, Humar A. 2019. Cytomegalovirus in solid organ transplant recipients-
233 Guidelines of the American Society of Transplantation Infectious Diseases
234 Community of Practice. *Clin Transplant* 33:e13512.
- 235 6. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar
236 A, The Transplantation Society International CMVCG. 2018. The Third International
237 Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ
238 Transplantation. *Transplantation* 102:900-931.
- 239 7. Razonable RR, Inoue N, Pinninti SG, Boppana SB, Lazzarotto T, Gabrielli L,
240 Simonazzi G, Pellett PE, Schmid DS. 2020. Clinical Diagnostic Testing for Human
241 Cytomegalovirus Infections. *J Infect Dis* 221:S74-S85.
- 242 8. Beam E, Germer JJ, Lahr B, Yao JDC, Limper AH, Binnicker MJ, Razonable RR.
243 2018. Cytomegalovirus (CMV) DNA quantification in bronchoalveolar lavage fluid of
244 immunocompromised patients with CMV pneumonia. *Clin Transplant* 32.
- 245 9. Boeckh M, Stevens-Ayers T, Travi G, Huang ML, Cheng GS, Xie H, Leisenring W,
246 Erard V, Seo S, Kimball L, Corey L, Pergam SA, Jerome KR. 2017. Cytomegalovirus
247 (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem
248 Cell Transplant Recipients With CMV Pneumonia. *J Infect Dis* 215:1514-1522.

- 249 10. Pinana JL, Gimenez E, Gomez MD, Perez A, Gonzalez EM, Vinuesa V, Hernandez-
250 Boluda JC, Montoro J, Salavert M, Tormo M, Amat P, Moles P, Carretero C,
251 Balaguer-Rosello A, Sanz J, Sanz G, Solano C, Navarro D. 2019. Pulmonary
252 cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell
253 transplant recipients: Implications for the diagnosis of CMV pneumonia. *J Infect*
254 78:393-401.
- 255 11. Saksirisampant G, Kawamatawong T, Promsombat K, Sukkasem W, Liamsombut S,
256 Pasomsub E, Bruminhent J. 2022. A Prospective Study of Plasma and
257 Bronchoalveolar Lavage Fluid CMV DNA Load Quantification for the Diagnosis and
258 Outcome of CMV Pneumonitis in Immunocompromised Hosts. *J Clin Virol*
259 155:105243.
- 260 12. Maschke M, Kastrup O, Diener HC. 2002. CNS manifestations of cytomegalovirus
261 infections: diagnosis and treatment. *CNS Drugs* 16:303-15.
- 262 13. Bewig B, Haacke TC, Tiroke A, Bastian A, Bottcher H, Hirt SW, Rautenberg P,
263 Haverich A. 2000. Detection of CMV pneumonitis after lung transplantation using
264 PCR of DNA from bronchoalveolar lavage cells. *Respiration* 67:166-72.
- 265 14. Lee HY, Rhee CK, Choi JY, Lee HY, Lee JW, Lee DG. 2017. Diagnosis of
266 cytomegalovirus pneumonia by quantitative polymerase chain reaction using
267 bronchial washing fluid from patients with hematologic malignancies. *Oncotarget*
268 8:39736-39745.

269

270 **Figure Legends**

271

272 **Figure 1.** Alinity m CMV assay linearity for dilution series in (A) plasma, (B) BAL, and (C)

273 CSF.

274

275 **Figure 2.** Levey-Jennings plots of (A) high and (B) low external QC. The dashed line

276 represents the 2SD acceptable range and the dotted line represents the 3SD acceptable

277 range.

278

279 **Figure 3.** Comparison of Alinity m CMV and RealTime CMV assay performance in plasma,

280 BAL, and CSF. (A) Deming regression of 97 plasma specimens within the quantifiable range

281 of both assays and (B) Bland-Altman plot of bias. (C) Deming regression of 40

282 bronchoalveolar lavage (BAL) specimens within the quantifiable range of both assays and

283 (D) Bland-Altman plot of bias. (E) Deming regression of 6 contrived CSF specimens within

284 the quantifiable range of both assays and (F) Bland-Altman plot of bias. The dashed line in

285 all Bland-Altman plots represents the average bias.

286

287 **Tables**

288 **Table 1.** Precision of the Alinity m CMV Assay

	Level (log ₁₀ IU/mL)	Mean (log ₁₀ IU/mL)	SD (log ₁₀ IU/mL)	% <2SD	Inter-assay %CV	Intra-assay %CV
EQC	N/A	5.95	0.08	100	1.31	1.09
	N/A	3.18	0.09	100	2.91	2.32
Plasma	5.70	5.68	0.07	100	1.27	0.84
	3.00	3.05	0.11	100	3.45	2.24
BAL	6.60	6.33	0.13	100	2.04	1.32
	4.60	4.59	0.06	100	1.38	1.17
	2.60	2.58	0.12	93	4.74	3.76
CSF	6.60	6.59	0.09	100	1.32	1.02
	4.60	4.81	0.07	93	1.44	0.71
	2.60	2.75	0.06	100	2.12	1.87

289 BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CV coefficient of variation; N/A, not
290 available; SD, standard deviation; EQC, external kit quality control material.

291 **Table 2.** Agreement Between RealTime CMV Assay and Alinity m CMV Assay for Plasma,
 292 BAL, and CSF
 293

Plasma Specimens (N=190)		RealTime		Positive Agreement	Negative Agreement	Overall Agreement
		Detected	Not Detected			
Alinity m	Detected	108	8	95%	89%	93%
	Not Detected	6	68			
BAL Specimens (N=78)		RealTime		Positive Agreement	Negative Agreement	Overall Agreement
		Detected	Not Detected			
Alinity m	Detected	48	4	100%	87%	95%
	Not Detected	0	26			
CSF Specimens (N=26)		RealTime		Positive Agreement	Negative Agreement	Overall Agreement
		Detected	Not Detected			
Alinity m	Detected	6	0	100%	100%	100%
	Not Detected	0	20			

294

Figure 1




Figure 2




Figure 3

